GP120

GP120 詳細

英語名HIV envelope protein gp120市販薬剤の数2
治験薬の数14ターゲットの別称HIV Envelope Protein gp120
研究&開発段階Approved
英語名HIV envelope protein gp120
ターゲットの別称HIV Envelope Protein gp120
市販薬剤の数2
治験薬の数14
研究&開発段階Approved

お問い合わせ

GP120バックグランド

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses.Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

GP120分子の別称

GP120,GP120-CN54

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Zinlirvimab10-1074; 10-1074-LS; GS-2872Phase 2 ClinicalThe Rockefeller UniversityHIV Infections; Acquired Immunodeficiency Syndrome
詳細
PGT121.414.LSVRC-HIVMAB0107-00-ABPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
詳細
PGT-121PGT-121Phase 2 ClinicalInternational Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And HarvardHIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral
詳細
Teropavimab3BNC117-LS-J; 3BNC117-LS; 3BNC117; GS-5423Phase 2 ClinicalThe Rockefeller UniversityHIV Infections; Acquired Immunodeficiency Syndrome
詳細
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung)Phase 1 ClinicalPolymun Scientific GmbhHIV Infections
詳細
PDPHV-201401PDPHV-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
詳細
ElipovimabGS-9722Phase 1 ClinicalGilead IncHIV Infections
詳細
VRC-HIVAAV070-00-GTAAV8-VRC07Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
詳細
Microbicide Monoclonal Antibody Triple Combination (Polymun)Phase 1 ClinicalHIV Infections
詳細
env (A, B, C, A/E)/gag DNA Vaccine(NIAID)PD-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
詳細
Vrc-Hivmab0121-00-AbCAP256J3LSPhase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
詳細
FB-1002(Frontier Biotechnologies)FB-1002(前沿生物)Phase 1 ClinicalFrontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
詳細
DS-003DS-003; BMS-793Phase 1 ClinicalBristol-Myers Squibb CompanyHIV Infections; Neoplasms
詳細
A-1801A-1801ClinicalWuhan BioRaid Biotechnology Co LtdHIV Infections
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Radha-108ApprovedBiomix NetworkReceptolHIV Infections
詳細
Fostemsavir TromethamineBMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrugApprovedBristol-Myers Squibb CompanyRukobiaUnited StatesHIV InfectionsViiv Healthcare Co2020-07-02HIV Infections
詳細
  • 詳細
  • お問い合わせ
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8